Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation.
We investigated the impact of metabolic syndrome (MS) on the occurrence of in-stent restenosis (ISR) and long-term major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, and target vessel revascularization (TVR) during a follow-up period of 36 months after percutaneous coronary intervention (PCI) with stent implantation in patients with significant preexisting coronary artery disease. MS was not an independent predictor of increased ISR and MACE after PCI.
Kim
Jeong Su
JS
Division of Cardiology, Department of Internal Medicine, College of Medicine, Pusan National, University, Medical Institute, Pusan Medical University Hospital, 10 Ami-dong 1-ga Seo-gu, Busan 602-739, Republic of Korea.
Lee
Han Cheol
HC
Choi
Bo-Kyung
BK
Lee
Hye-Won
HW
Park
Jin-Sup
JS
Lee
Yong Hwan
YH
Ahn
Min-Soo
MS
Hong
Taek Jong
TJ
Kim
Sang-Pil
SP
Lee
Sang-Kwon
SK
Kim
Yeong Dae
YD
D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D003327:Coronary Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000453:epidemiology*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000209:etiology / Q000401:mortality; D011183:Postoperative Complications; D012189:Retrospective Studies; D015607:Stents; D015996:Survival Rate; D016896:Treatment Outcome